safusidenib

Phase 3Small molecule

NNuvation Bio Inc.

safusidenib is one of 49 small molecule programs targeting IDH1 Mutation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IDH1 MutationNot yet recruiting

IDH1-Mutant GliomaNot yet recruiting

GliomaRecruiting

IDH1 MutationPhase 3

Not yet recruiting

IDH1-Mutant GliomaPhase 2

Not yet recruiting

GliomaPhase 3

Recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Camptosar

Pfizer

Phase 2

5 7

Keytruda

Merck & Co.

Phase 2

5 8

Lynparza

AstraZeneca

Phase 2

3 9

Verzenio

Eli Lilly

Phase 2

3 10

Dostarlimab

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Glioma

NCT05303519

Q1 2032

Phase 2Not yet recruiting

IDH1-Mutant Glioma

NCT07703436

Phase 3Not yet recruiting

IDH1 Mutation

NCT07712757

Clinical

Trials by Indication[1]

Glioma1 trial

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Recruiting·NNuvation Bio Inc.·Phase 3·NCT05303519·365 enrolled

IDH1-mutant Glioma1 trial

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Not yet recruiting·NNuvation Bio Inc.·Phase 2·NCT07703436·40 enrolled

IDH1 Mutation1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Not yet recruiting·NNuvation Bio Inc.·Phase 3·NCT07712757·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for safusidenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — safusidenib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for safusidenib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuvation Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNuvation Bio Inc.

safusidenib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Q1 2032

Trials by Indication[1]

Glioma1 trial

IDH1-mutant Glioma1 trial

IDH1 Mutation1 trial

References

Drug Info

Quick Facts

Related News